drugset / Trial / NCT06477939
Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients
Phase 3
Not yet recruiting
554 enrolled
Institut de cancérologie Strasbourg Europe
LEAF4Life, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is phase III randomized, multicenter study adding or not intra-venous Liposomal Trasncrocetin (L-TC) to hypofractionated radiotherapy and concomitant Temozolomide followed by adjuvant Temozolomide in patients with histologically confirmed diagnosis of glioblastoma (GBM).
Timeline
- Start
- 2025-01-01
- Primary completion
- 2032-12-31
- Completion
- 2032-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Transcrocetin | Unknown | 300 mg | Intravenous |
| Background | Temozolomide | Small molecule | 75 mg/m2 | — |